Diabetic nephropathy is the commonest cause of Glycosylated haemoglobin was >9.1% in 29%. Twenty were prescribed medications inappropriate end-stage renal failure in the developed world. The quality of care of 152 patients with diabetic nephroto their renal function. Of patients with ischaemic heart disease and serum cholesterol >5.5 mmol/l, pathy was assessed at the time of referral to a single nephrologist. The type II diabetics (62%) were older 82% were untreated; 82% of patients with secondary hyperparathyroidism were also untreated. At than the type I diabetics (38%) (mean 65 years vs. 48 years). The mean duration of diabetes was 17 initial referral, many patients' care was sub-optimal. Referral was too late for adequate preparation for years. Significant cardiovascular disease was present in 52%. There was diabetic retinopathy in 84% of renal replacement therapy in 33%. Following a process of education and feedback of the results to the type I diabetics and 53% of the type II diabetics. Overall, 63% had hypertension at referral (St referring practitioners, the timing of referral improved. We emphasize the need for closer Vincent Declaration criteria), untreated in 25%. ACE inhibitors were not prescribed in 48% when co-operation between those managing diabetic patients with nephropathy to optimize their care. no contraindications to their use were present.
Introduction
Despite recent advances in the management of with 37% for other patients, 10-year figures are 12% and 22%, respectively.1 In Italy, the respective 5-year diabetes, diabetic nephropathy is the most frequent cause of end-stage renal failure in patients commensurvival figures are 28% and 61%. 4 The rate of progression of renal impairment once cing renal replacement therapy (RRT) in the developed world, e.g. 40% in the USA,1 42% in overt diabetic nephropathy is established varies greatly between patients, but the mean time interval Germany,2 14% in the UK,3 and 10% in Italy. 4 Approximately 20% of patients with type I diabetes from onset of nephropathy to commencing RRT is 6.5 years for both types of diabetes.6 will develop nephropathy after 20 years, with a slightly higher cumulative incidence in type II diaThere is debate whether therapy influences the progression of established diabetic nephropathy, betics.5
Type II diabetics comprise an increasing proporhowever evidence exists for the effectiveness of blood pressure control,7 treatment with ACE inhibtion of the diabetics starting RRT, and in many developed countries are in the majority.1,2 Once itors,8,9 non-dihydropyridine calcium channel blockers,10 restriction of dietary protein intake,11,12 and commenced on RRT, diabetics have an increased morbidity, a hospitalization rate two to three times treatment of dyslipidaemia.13 Thus, even when diabetic nephropathy is established, patients' care that of other patients on RRT,4 and a significantly worse survival and outcome. In the USA, 5-year should be optimized to delay the progression of nephropathy, and hence the need for RRT. survival of diabetics on RRT is only 28% compared
The St Vincent Declaration of 1989 was a World nephrologists were also offered. The data from the subsequent 52 patients, referred between October Health Organization initiative aimed at improving diabetic care.14 In 1992, the European St Vincent 1996 and July 1998, were later analysed separately as well as with the whole group. Declaration Action Programme 199215 set down more specific guidelines for the prevention and management of diabetic nephropathy. For overt diabetic nephropathy, these include keeping blood (Table 2) , 56 (96%) type I diabetics, and 61 (64%) at the time of referral of diabetic patients to this type II diabetics were attending a specialist diabetic renal clinic, such recommendations were being folclinic. In 22 of the 152 patients in whom there was lowed, and whether interventions appropriate to the doubt regarding the diagnosis of diabetic nephroevidence had been applied.
pathy, this was confirmed by renal biopsy.
Blood pressure
Methods
The blood pressures recorded are summarized in Included in this study are 152 patients from a total Table 3 . Overall, 63% were hypertensive at referral, of 162 patients consecutively referred to a single and 24% were normotensive but on antihypertensive consultant nephrologist for diabetic nephropathy over therapy, giving a total incidence of hypertension in a 6-year period (1991) (1992) (1993) (1994) (1995) (1996) (1997) , from a catchment area this population of 87%. Many hypertensive patients including eight diabetic clinics, and general practiwere not receiving treatment. Of those aged under tioner clinics, serving a population of 1.5 million.
60 with a BP>140/90 mmHg (48 patients), 14 (29%) Ten patients were excluded from the study, as
were not receiving treatment, and of the 47 patients investigation revealed other predominant renal disaged over 60 whose BP was >160/90 mmHg, 11 ease. Diagnosis was on clinical grounds (significant (23%) were untreated. albuminuria>300 mg/day, or random albumin5cre-atinine ratio>20 g/mmol, and a renal ultrasound
Use of ACE inhibitors
scan showing near-equal-sized non-scarred kidneys). Renal biopsy was only performed if there was clinical At referral, 67 patients (44%) were on ACE inhibitors; doubt as to the diagnosis. The absence of diabetic these had been discontinued prior to referral in nine retinopathy on ophthalmoscopy was not of itself patients because of complications (marked deterioraconsidered an indication for renal biopsy.
tion of renal function in six, hyperkalaemia in two, Patient assessment at referral included a medicaintractable cough in one), and had been deliberately tion and smoking history, evidence of arteriopathy avoided in a further three patients because of the and retinopathy, cardiac assessment, blood pressure, presence of severe atherosclerotic disease and risk serum creatinine, serum cholesterol, HbA 1c , immunoof renovascular disease. reactive parathyroid hormone (iPTH), calcium and phosphate. All data were entered into computerized Vascular disease, retinopathy, and history of case records. The blood pressure measurement used smoking for this analysis was that recorded at the second visit to the renal clinic to avoid the effects of anxiety Assessment of the presence of atherosclerotic vascular disease is summarized in Table 4 . Of those with associated with the initial referral.
Data from the first 100 patients, referred between retinopathy, 59 (60%) had a positive smoking history, compared with 27 (51%) patients without retinopaNovember 1991 and September 1996, were analysed. The results of this initial analysis were prethy. Table 5 summarizes the results of comparing the relationship of atherosclerotic vascular disease with sented to the local GPs, diabetologists and other physicians as part of a continuing programme of smoking history. Whilst an association between the two factors appeared to be present, this was not dialogue, audit, and education. Recommendations on the appropriate management of nephropathic statistically significant. At referral, 30 patients (20%) were current smokers (11 female), and 54 (36%) diabetics, and the optimal timing of referral to patients were ex-smokers (13 female). Of those who recommended level requiring treatment,18 and this was untreated in 17 (82%). Eighteen patients were had stopped smoking before referral, half had stopped after being diagnosed diabetic.
receiving treatment for hypercholesterolaemia, eight with statins, and 10 with fibrates. In six patients the prescriptions of fibrates were considered inappropri-
Control of diabetes
ate for their degree of renal impairment (serum Assessment of diabetic control by HbA 1c was availcreatinine >300 mmol/l.16 able in 118 patients at referral. In other patients, serum fructosamine levels had been used to assess control. Of the 118 patients, 39 patients (34%) had
Secondary hyperparathyroidism
good control (HbA 1c <7.0%), 34 patients (29%) had The 76 patients whose serum creatinine exceeded poor control (HbA 1c >9.1%). At referral, 68 patients 250 mmol/l were assessed to determine whether (45%) were taking oral hypoglycaemic agents, and secondary hyperparathyroidism had been sought and 32 type II diabetics (34%) were taking insulin. Of appropriately managed. The criteria used to assess the patients taking oral hypoglycaemic agents, 22 'appropriate' management were those recommended were taking Metformin, and 21 Glibenclamide, by the Renal Association in 1995.19 Forty-three which were inappropriate prescriptions in 14 (33%) patients (57%) had evidence of secondary hyperparain view of their degree of renal impairment thyroidism, of whom only eight (18%) were receiving (serum creatinine>300 mmol/l for Metformin, and treatment. This pathology had often been overlooked, >700 mmol/l for Glibenclamide). 16 as over 70% of patients had not had serum iPTH measured prior to referral.
Serum cholesterol
The few recommendations which exist for the man-
Timing of referral
agement of hyperlipidaemia in diabetes recommend that levels >6.2 mmol/l are too high, and that the The St Vincent Declaration recommends nephrology referral when serum creatinine exceeds 200 mmol/l, desired therapeutic goal should be <5.2 mmol/l.17 At referral, only 40 patients (26%) had serum cholesto enable management of renal failure and adequate preparation for RRT. In this study, 50 (33%) patients terol <5.2 mmol/l, and 57 (38%) had serum cholesterol >6.2 mmol/l, of whom 82% were untreated.
were referred when their serum creatinine was >350 mmol/l, and 29 patients (19%) when their Of the 33 patients with coronary artery disease, 21 (63%) had a serum cholesterol >5.5 mmol/l, the serum creatinine was >500 mmol/l. Twenty-five patients (16%) required RRT within 6 months of in diabetic patients. 24 Clinical trials have established referral, 13 (9%) within 6 weeks of referral.
that treatment of hypercholesterolaemia reduces the There appeared to be a change in referral pattern risk of coronary artery disease morbidity and mortalduring the study. The last 52 patients were referred ity in the setting of both primary25 and secondary26 at an earlier stage of their disease as judged by prevention. Recommendations are that patients with serum creatinine and time to needing RRT (Table 6) . coronary artery disease with serum cholesterol The rate of referral also appeared to increase.
>5.5 mmol/l should be treated.18 Of 33 diabetics with documented coronary heart disease, 21 had a serum cholesterol >5.5 mmol/l, which was untreated in 82%.
Discussion
In primary prevention, initiation of treatment A number of studies have elucidated the risk factors depends on the number of other risk factors for for progression to end-stage renal failure in diabetic cardiovascular disease present.27 Studies have shown nephropathy.12,20,21 Management strategies have diabetes to be a strong independent risk factor for been identified which may slow the rate of deterioracardiovascular disease mortality, even when other tion of renal function. Whilst accepting that the established risk factors are absent (hypertension, desirable targets for such variables as blood pressure cigarette smoking, hypercholesterolaemia).24 Thus and serum cholesterol are not always achievable, whether or not hypercholesterolaemia is a causative this study suggests that possible action is not always factor in diabetic nephropathy, treatment of hypertaken, and is frequently inadequate. cholesterolaemia is important in diabetic patients to There has been criticism that the St Vincent reduce the risk of coronary artery disease. Of the recommendations for treatment of hypertension in 152 patients referred, 111 (73%) had a serum cholesthe elderly are not strict enough. Whilst achieving a terol >5.2 mmol/l, of whom 25 (23%) had evidence pressure of 140/90 or less is difficult in this group, of ischaemic heart disease, and 74 (67%) had two there is no evidence that lowering the pressure to or more risk factors for ischaemic heart disease. Of this level is of any less value in the elderly than in these latter 99 patients, only 15 were receiving younger patients.22,23 Even accepting the relatively cholesterol-lowering treatment. liberal St Vincent criteria, at referral 87% of patients It is disappointing that 21 (14%) were receiving were or had been hypertensive, and 63% still had drugs inappropriate for their degree of renal dysfuncblood pressure higher than recommended. Of those tion (9 metformin, 5 glibenclamide, 6 fibrates). In aged under 60 who were hypertensive, 29% were four cases, a fibrate was contributing to significant not receiving therapy. These findings are disapsymptoms, which resolved when the drug was pointing, as apart from the potential benefits for stopped. protecting renal function, diabetics gain more from
The optimal timing for referral of nephropathic treatment of hypertension in terms of reducing patients, stated in the St Vincent Declaration, is cardiovascular mortality than non-diabetic hypertenswhen serum creatinine exceeds 200 mmol/l. We ive patients. 22, 23 assessed referrals as being acceptable in patients The literature on the protective effect of ACE whose serum creatinine was below 350 mmol/l; 50 inhibitors in diabetic nephropathy is convincing. referrals (33%) did not meet this standard. Nevertheless 48% of these overtly nephropathic
The timing of referral of any patient with renal patients were not prescribed ACE inhibitors: most of impairment to nephrologists is important, because of these were hypertensive and appeared to have no its impact on their subsequent management. Early contraindication to their use.
referral enables patient assessment, and the institution Atherosclerosis, in particular coronary artery disease, is a significant cause of morbidity and mortality of a management plan with specific aims. These For serum creatinine at referral >350 mmol/l and association with referral in first 100 patients, x2=12.21 ( p<0.001); for serum creatinine at referral >500 mmol/l and association with first 100 patients, x2=10.42 ( p=0.001).
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